Skip to main content
SpringerLink
Log in

Treatment of Myasthenia Gravis

  • Chapter
  • First Online:
Myasthenia Gravis and Related Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Effective therapy for the individual MG patient rests on balancing the risks and benefits of a wide range of therapeutic options. These risks not only include the dangers of severe weakness, limitations on employment, and complications of treatment but access to medications based on insurance company policies or government-set limitations. The typical patient who does not respond to cholinesterase inhibitor treatment will require prednisone and, if poorly responsive or with significant adverse effects, will need immunosuppressive therapy with azathioprine, tacrolimus, or mycophenolate. The treatment-resistant patient who fails corticosteroids and an immunosuppressive may benefit from a switch to another immunosuppressive or eculizumab. Despite the increasing number of excellently performed clinical trials, practice remains compromised by a limited evidence base, but the development of national guidelines for treatment has the promise of guiding clinicians not familiar with this rare disease to care for patients in a logical manner.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet. 1934;1:1200–1.

    Article  Google Scholar 

  2. Keesey JC. Contemporary opinions about Mary Walker: a shy pioneer of therapeutic neurology. Neurology. 1998;51(5):1433–9.

    Article  CAS  PubMed  Google Scholar 

  3. Remen L. Zur Pathogenese und Therapie der Myasthenia gravis pseudoparalytica. Dtsch Ztschr f Nervenheilkunde. 1932;128:66–78.

    Article  Google Scholar 

  4. Viets HR. Introductory remarks. In: Ossermann KE, editor. Myasthenia gravis, vol. 135. New York: New York Academy of Sciences; 1966. p. 5–7.

    Google Scholar 

  5. Bell ET. Tumors of the thymus in myasthenia gravis. J Nerv Ment Dis. 1917;45:130–43.

    Article  Google Scholar 

  6. Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg. 1939;110:544–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kirschner PA. The history of surgery of the thymus gland. Chest Surg Clin N Am. 2000;10(1):153–65.

    CAS  PubMed  Google Scholar 

  8. Blalock A. Thymectomy in treatment of myasthenia gravis. J Thorac Surg. 1944;13:316.

    Google Scholar 

  9. Blalock A, Harvey AM, Ford FF, Lilienthal JL. The treatment of myasthenia gravis by removal of the thymus gland: preliminary report. JAMA. 1941;117:1529.

    Article  Google Scholar 

  10. Rowland LP. Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry. 1980;43:644–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [see comments]. Neurology. 2000;55(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  12. Aban IB, Wolfe GI, Cutter GR, Kaminski HJ, Jaretzki A 3rd, Minisman G, et al. The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol. 2008;201–202:80–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Pinching AJ, Peters DK, Newsom-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet. 1976;2:1373–6.

    Article  CAS  PubMed  Google Scholar 

  14. Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6):909–17.

    Article  PubMed  Google Scholar 

  15. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–25.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fuhr P, Gold R, Hohlfeld R, Melms A, Melzer N, Tackenberg B, et al. Diagnostik und therapie der myasthenia gravis und des Lambert-Eaton syndroms. In: Diener H, Weimer C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. 5th ed. Stuttgart: Thieme; 2012. p. 830–56.

    Google Scholar 

  17. Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol. 2015;2015:21–31.

    Article  Google Scholar 

  18. Machado-Alba JE, Calvo-Torres LF, Gaviria-Mendoza A, Augusto Meji AVC. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis. Muscle Nerve. 2017;56(6):1041–6.

    Article  CAS  PubMed  Google Scholar 

  19. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36.

    Article  CAS  PubMed  Google Scholar 

  20. Priola AM, Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol. 2014;69(5):e230–45.

    Article  CAS  PubMed  Google Scholar 

  21. de Kraker M, Kluin J, Renken N, Maat AP, Bogers AJ. CT and myasthenia gravis: correlation between mediastinal imaging and histopathological findings. Interact Cardiovasc Thorac Surg. 2005;4(3):267–71.

    Article  PubMed  Google Scholar 

  22. Kaminski HJ, Santillan C, Wolfe GI. Autoantibody testing in neuromuscular disorders. Neuromuscular junction and muscle disorders. J Clin Neuromuscul Dis. 2000;2:96–105.

    Article  CAS  PubMed  Google Scholar 

  23. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dalakas MC. Immunotherapies in the treatment of neuromuscular disorders. In: Katirji B, Kaminski H, Preston D, Ruff R, Shapiro B, editors. Neuromuscular disorders in clinical practice. Boston: Butterworth Heinemann; 2002. p. 364–83.

    Google Scholar 

  25. Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Murai H, Imai T, et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve. 2014;50(4):493–500.

    Article  CAS  PubMed  Google Scholar 

  26. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–9.

    Article  PubMed  Google Scholar 

  27. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47:1233–8.

    Article  PubMed  Google Scholar 

  28. Somnier F, Keiding N, Paulson O. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive study. Arch Neurol. 1991;48:733–9.

    Article  CAS  PubMed  Google Scholar 

  29. Burns TM, Sanders DB, Kaminski HJ, Wolfe GI, Narayanaswami P, Venitz J. Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States. Muscle Nerve. 2015;51(5):635–7.

    Article  CAS  PubMed  Google Scholar 

  30. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011;31(10):691–701.

    Article  CAS  PubMed  Google Scholar 

  31. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2014;(10):CD006986.

    Google Scholar 

  32. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 2003;17(2):214–22.

    Article  CAS  PubMed  Google Scholar 

  33. Brenner T, Nizri E, Irony-Tur-Sinai M, Hamra-Amitay Y, Wirguin I. Acetylcholinesterase inhibitors and cholinergic modulation in myasthenia gravis and neuroinflammation. J Neuroimmunol. 2008;201–202:121–7.

    Article  PubMed  CAS  Google Scholar 

  34. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40.

    Article  PubMed  Google Scholar 

  35. Echaniz-Laguna A, Pistea C, Philippi N, Enache I, Oswald-Mammosser M, De Seze J, et al. Asthma as a cause of persistent dyspnea in treated myasthenia gravis patients. Eur Neurol. 2012;68(5):300–3.

    Article  PubMed  Google Scholar 

  36. Arsura EL, Brunner NG, Namba T, Grob D. Adverse cardiovascular effects of anticholinesterase medications. Am J Med Sci. 1987;293(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  37. Said S, Cooper CJ, Alkhateeb H, Elhanafi S, Bizet J, Gosavi S, et al. Pyridostigmine-induced high grade SA-block in a patient with myasthenia gravis. Am J Case Rep. 2013;14:359–61.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Daroff RB. Ocular myasthenia: diagnosis and therapy. In: Glaser J, editor. Neruo-opthalmology. St. Louis: C.V. Mosby; 1980. p. 62–71.

    Google Scholar 

  39. Daroff RB. The office tensilon test for ocular myasthenia gravis. Arch Neurol. 1986;43:843–4.

    Article  CAS  PubMed  Google Scholar 

  40. Juel VC, Massey JM. Autoimmune myasthenia gravis: recommendations for treatment and immunologic modulation. Curr Treat Options Neurol. 2005;7(1):3–14.

    Article  PubMed  Google Scholar 

  41. Edgeworth H. A report of progress on the use of ephedrine in a case of myasthenia gravi. JAMA. 1930;94:1136.

    Article  Google Scholar 

  42. Edgeworth H. The effect of ephedrine in the treatment of myasthenia gravis, second report. JAMA. 1933;100:1401.

    Article  Google Scholar 

  43. Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, et al. Ephedrine treatment for autoimmune myasthenia gravis. Neuromuscul Disord. 2017;27(3):259–65.

    Article  PubMed  Google Scholar 

  44. Evoli A, Alboini PE, Damato V, Iorio R. 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies. Neurology. 2016;86(11):1070–1.

    Article  PubMed  Google Scholar 

  45. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;(2):CD002828.

    Google Scholar 

  46. Hoffmann S, Kohler S, Ziegler A, Meisel A. Glucocorticoids in myasthenia gravis—if, when, how, and how much? Acta Neurol Scand. 2014;130(4):211–21.

    Article  CAS  PubMed  Google Scholar 

  47. Bedlack RS, Sanders DB. Steroids have an important role. Muscle Nerve. 2002;25(1):117–21.

    Article  PubMed  Google Scholar 

  48. Rivner MH. Steroids are overutilized. Muscle Nerve. 2002;25(1):115–7.

    Article  PubMed  Google Scholar 

  49. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570–81.

    Article  CAS  PubMed  Google Scholar 

  50. Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol. 1992;32(1):37–43.

    Article  CAS  PubMed  Google Scholar 

  51. Xie Y, Li H-F, Sun L, Kusner LL, Wang S, Meng Y, et al. The role of osteopontin and its gene on glucorticoid response in myasthenia gravis. Front Neurol. 2017;8:230.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Xie Y, Meng Y, Li HF, Hong Y, Sun L, Zhu X, et al. GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. Eur J Neurol. 2016;23(8):1372–9.

    Article  CAS  PubMed  Google Scholar 

  53. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13(10):1006–10.

    Article  CAS  PubMed  Google Scholar 

  54. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291–8.

    Article  CAS  PubMed  Google Scholar 

  55. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al. Prognosis of myasthenia gravis: a multicenter follow-up study. J Neurol Sci. 1991;106:213–20.

    Article  CAS  PubMed  Google Scholar 

  56. Seybold M, Drachman D. Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment. N Engl J Med. 1974;290:81–4.

    Article  CAS  PubMed  Google Scholar 

  57. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472–99.

    Article  CAS  PubMed  Google Scholar 

  58. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychiatry. 1991;54:406–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797–810.

    Article  CAS  PubMed  Google Scholar 

  60. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–22.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Wolfe GI, Kaminski HJ, Jaretzki A 3rd, Swan A, Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci. 2003;998:473–80.

    Article  CAS  PubMed  Google Scholar 

  62. Group MS. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394–9.

    Article  CAS  Google Scholar 

  63. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn E, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Lewis SJ, Smith PE. Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand. 2001;103(5):320–2.

    Article  CAS  PubMed  Google Scholar 

  65. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4(5):e004587.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Brown ES, Vera E, Frol AB, Woolston DJ, Johnson B. Effects of chronic prednisone therapy on mood and memory. J Affect Disord. 2007;99(1–3):279–83.

    Article  CAS  PubMed  Google Scholar 

  67. Perantie DC, Brown ES. Corticosteroids, immune suppression, and psychosis. Curr Psychiatry Rep. 2002;4(3):171–6.

    Article  PubMed  Google Scholar 

  68. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Quax RA, Manenschijn L, Koper JW, Hazes JM, Lamberts SW, van Rossum EF, et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol. 2013;9(11):670–86.

    Article  CAS  PubMed  Google Scholar 

  70. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778–83.

    Article  CAS  PubMed  Google Scholar 

  71. Heckmann JM, LeePan EB, Eastman RW. High-dose immunosuppressive therapy in generalised myasthenia gravis—a 2-year follow-up study. S Afr Med J. 2001;91(9):765–70.

    CAS  PubMed  Google Scholar 

  72. Cosi V, Lombardi M, Erbetta A, Piccolo G. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis. Acta Neurol (Napoli). 1993;15(2):123–31.

    CAS  Google Scholar 

  73. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235:449–53.

    Article  CAS  PubMed  Google Scholar 

  74. Gupta A, Goyal V, Srivastava AK, Shukla G, Behari M. Remission and relapse of myasthenia gravis on long-term azathioprine: an ambispective study. Muscle Nerve. 2016;54(3):405–12.

    Article  CAS  PubMed  Google Scholar 

  75. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984;15:602–5.

    Article  CAS  PubMed  Google Scholar 

  76. Jack KL, Koopman WJ, Hulley D, Nicolle MW. A review of azathioprine-associated hepatotoxicity and myelosuppression in myasthenia gravis. J Clin Neuromuscul Dis. 2016;18(1):12–20.

    Article  PubMed  Google Scholar 

  77. Sanders D, Howard F Jr. Disorders of neuromuscular transmission. In: Bradley W, Daroff R, Fenichel G, Marsden C, editors. Neurology in clinical practice. Boston: Butterworth Heinemann; 2000. p. 2167–85.

    Google Scholar 

  78. Pedersen EG, Pottegard A, Hallas J, Friis S, Hansen K, Jensen PE, et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol. 2013;20(6):942–8.

    Article  CAS  PubMed  Google Scholar 

  79. Machkhas H, Harati Y, Rolak LA. Clinical pharmacology of immunosuppressants: guidelines for neuroimmunotherapy. In: Rolak LA, Harati Y, editors. Neuroimmunology for the clinician. Boston: Butterworth Heinemann; 1997. p. 77–104.

    Google Scholar 

  80. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85(7):647–54.

    Article  CAS  PubMed  Google Scholar 

  81. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014;77(4):704–14.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8(1):24–36.

    Article  CAS  PubMed  Google Scholar 

  84. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology. 2001;56(1):97–9.

    Article  CAS  PubMed  Google Scholar 

  85. Chaudhry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56(1):94–6.

    Article  CAS  PubMed  Google Scholar 

  86. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003;998:494–9.

    Article  CAS  PubMed  Google Scholar 

  87. Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol. 2008;255(4):510–3.

    Article  CAS  PubMed  Google Scholar 

  88. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–6.

    Article  CAS  PubMed  Google Scholar 

  89. Benatar M, Rowland LP. The muddle of mycophenolate mofetil in myasthenia. Neurology. 2008;71(6):390–1.

    Article  PubMed  Google Scholar 

  90. Hobson-Webb LD, Hehir M, Crum B, Visser A, Sanders D, Burns TM. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. Muscle Nerve. 2015;52(2):211–5.

    Article  PubMed  Google Scholar 

  91. Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4(2):42–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Buell C, Koo J. Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol. 2008;7(8):741–8.

    PubMed  Google Scholar 

  93. O’Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(10):1186–91.

    Article  PubMed  Google Scholar 

  94. Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65(4):639–41.

    Article  PubMed  Google Scholar 

  95. Termsarasab P, Katirji B. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil. J Neuroimmunol. 2012;249(1–2):83–5.

    Article  CAS  PubMed  Google Scholar 

  96. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today (Barc). 2009;45(7):521–32.

    CAS  Google Scholar 

  97. Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci. 2011;300(1–2):59–62.

    Article  CAS  PubMed  Google Scholar 

  98. Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, et al. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol. 2011;11(4):519–24.

    Article  CAS  PubMed  Google Scholar 

  99. Cruz JL, Wolff ML, Vanderman AJ, Brown JN. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord. 2015;8(2):92–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970–7.

    Article  PubMed  Google Scholar 

  101. Benatar M, Sanders D. The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):945.

    Article  PubMed  Google Scholar 

  102. Yagi Y, Sanjo N, Yokota T, Mizusawa H. Tacrolimus monotherapy: a promising option for ocular myasthenia gravis. Eur Neurol. 2013;69(6):344–5.

    Article  PubMed  Google Scholar 

  103. Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, et al. Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol. 2017;24(2):270–5.

    Article  CAS  PubMed  Google Scholar 

  104. Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013;191(12):5785–91.

    Article  CAS  PubMed  Google Scholar 

  105. MacMillan D. FK506 binding proteins: cellular regulators of intracellular Ca2+ signalling. Eur J Pharmacol. 2013;700(1–3):181–93.

    Article  CAS  PubMed  Google Scholar 

  106. Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol. 2008;195(1–2):108–15.

    Article  CAS  PubMed  Google Scholar 

  107. Imai T, Tsuda E, Hozuki T, Yamauchi R, Saitoh M, Hisahara S, et al. Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis. Clin Neurophysiol. 2012;123(9):1886–90.

    Article  CAS  PubMed  Google Scholar 

  108. Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87(1):57–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47(3):249–55.

    Article  CAS  Google Scholar 

  111. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–51.

    Article  CAS  PubMed  Google Scholar 

  112. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55(3):448–50.

    Article  CAS  PubMed  Google Scholar 

  113. Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand. 2005;111(4):247–52.

    Article  CAS  PubMed  Google Scholar 

  114. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4):CD005224.

    Google Scholar 

  115. Tamler R, Epstein S. Nonsteroid immune modulators and bone disease. Ann N Y Acad Sci. 2006;1068:284–96.

    Article  CAS  PubMed  Google Scholar 

  116. Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med. 2007;28(4):398–417.

    Article  PubMed  Google Scholar 

  117. Nagappa M, Netravathi M, Taly AB, Sinha S, Bindu PS, Mahadevan A. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci. 2014;21(11):1909–14.

    Article  CAS  PubMed  Google Scholar 

  118. Drachman DB, Brodsky RA. High-dose therapy for autoimmune neurologic diseases. Curr Opin Oncol. 2005;17(2):83–8.

    Article  PubMed  Google Scholar 

  119. Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol. 2016;73(6):652–8.

    Article  PubMed  Google Scholar 

  120. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369–83.

    Article  CAS  PubMed  Google Scholar 

  121. Stieglbauer K, Pichler R, Topakian R. 10-year-outcomes after rituximab for myasthenia gravis: efficacy, safety, costs of inhospital care, and impact on childbearing potential. J Neurol Sci. 2017;375:241–4.

    Article  CAS  PubMed  Google Scholar 

  122. Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185–96.

    Article  CAS  PubMed  Google Scholar 

  123. Anderson D, Phan C, Johnston WS, Siddiqi ZA. Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol. 2016;3(7):552–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Robeson KR, Kumar A, Keung B, DiCapua DB, Grodinsky E, Patwa HS, et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol. 2017;74(1):60–6.

    Article  PubMed  Google Scholar 

  125. Hehir M, Hobson-Webb L, Benatar M, Barnett C, Silvestri N, Howard J, et al. Rituximab is an effective treatment for anti-MuSK myasthenia gravis. Neurology. 2017;89(10):1069–77.

    Article  CAS  PubMed  Google Scholar 

  126. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus. 2005;14(3):210–4.

    Article  CAS  PubMed  Google Scholar 

  127. Luu VP, Vazquez MI, Zlotnik A. B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity. 2014;47(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  128. Kusner LL, Kaminski HJ. The role of complement in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci. 2012;1274:127–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84.

    Article  CAS  PubMed  Google Scholar 

  130. Howard JF Jr, Utsugisawa K, Benatar M, Murai M, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R, Regain Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.

    Article  CAS  PubMed  Google Scholar 

  131. Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104(5):548–58.

    Article  CAS  PubMed  Google Scholar 

  133. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–9.

    Article  CAS  PubMed  Google Scholar 

  134. Razzak M. Anaemia: mutations in C5 explain eculizumab resistance. Nat Rev Nephrol. 2014;10(4):182.

    Article  PubMed  Google Scholar 

  135. Guptill JT, Oakley D, Kuchibhatla M, Guidon AC, Hobson-Webb LD, Massey JM, et al. A retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve. 2013;47(2):170–6.

    Article  PubMed  Google Scholar 

  136. Mandawat A, Kaminski HJ, Shaker ZA, Alawi AA, Alshekhlee A. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve. 2011;43(4):578–84.

    Article  PubMed  Google Scholar 

  137. Kohler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher. 2011;26(6):347–55.

    Article  PubMed  Google Scholar 

  138. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;(4):CD002275.

    Google Scholar 

  139. Haupt WF, Rosenow F, van der Ven C, Birkmann C. Immunoadsorption in Guillain-Barre syndrome and myasthenia gravis. Ther Apher. 2000;4(3):195–7.

    Article  CAS  PubMed  Google Scholar 

  140. Grob D, Simpson D, Mitsumoto H, Hoch B, Mokhtarian F, Bender A, et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology. 1995;45(2):338–44.

    Article  CAS  PubMed  Google Scholar 

  141. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22(5):270–6.

    Article  PubMed  Google Scholar 

  142. Vincent A. John Newsom-Davis: clinician-scientist and so much more. Brain. 2011;134(Pt 12):3755–74.

    Article  PubMed  Google Scholar 

  143. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68(6):797–805.

    Article  PubMed  Google Scholar 

  145. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837–41.

    Article  CAS  PubMed  Google Scholar 

  146. Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52(3):629–32.

    Article  CAS  PubMed  Google Scholar 

  147. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008;(1):CD002277.

    Google Scholar 

  148. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–55.

    Article  CAS  PubMed  Google Scholar 

  149. Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol. 1993;13(4):272–8.

    Article  CAS  PubMed  Google Scholar 

  150. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313–8.

    Article  CAS  PubMed  Google Scholar 

  151. Vucic S, Chong PS, Dawson KT, Cudkowicz M, Cros D. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol. 2004;52(3):141–4.

    Article  CAS  PubMed  Google Scholar 

  152. Luzi G, Bongiorno F, Paparo Barbaro S, Bruno G. Intravenous IgG: biological modulating molecules. J Biol Regul Homeost Agents. 2009;23(1):1–9.

    CAS  PubMed  Google Scholar 

  153. Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol. 2006;176(1–2):187–97.

    Article  CAS  PubMed  Google Scholar 

  154. Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2008;194(1–2):89–96.

    Article  CAS  PubMed  Google Scholar 

  155. Norwood F, Dhanjal M, Hill M, James N, Jungbluth H, Kyle P, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014;85(5):538–43.

    Article  PubMed  Google Scholar 

  156. Batocchi AP, Majolini L, Evoli A, Lino MM, Minisci C, Tonali P. Course and treatment of myasthenia gravis during pregnancy. Neurology. 1999;52(3):447–52.

    Article  CAS  PubMed  Google Scholar 

  157. Plauché WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol. 1991;34:82–99.

    Article  PubMed  Google Scholar 

  158. Ducci RD, Lorenzoni PJ, Kay CS, Werneck LC, Scola RH. Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord. 2017;27(4):352–7.

    Article  PubMed  Google Scholar 

  159. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007;14(1):38–43.

    Article  CAS  PubMed  Google Scholar 

  160. Ciafaloni E, Massey JM. The management of myasthenia gravis in pregnancy. Semin Neurol. 2004;24(1):95–100.

    Article  PubMed  Google Scholar 

  161. Kalidindi M, Ganpot S, Tahmesebi F, Govind A, Okolo S, Yoong W. Myasthenia gravis and pregnancy. J Obstet Gynaecol. 2007;27(1):30–2.

    Article  CAS  PubMed  Google Scholar 

  162. Wen JC, Liu TC, Chen YH, Chen SF, Lin HC, Tsai WC. No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a nationwide population-based study. Eur J Neurol. 2009;16(8):889–94.

    Article  PubMed  Google Scholar 

  163. O’Carroll P, Bertorini TE, Jacob G, Mitchell CW, Graff J. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. J Clin Neuromuscul Dis. 2009;11(2):69–71.

    Article  PubMed  Google Scholar 

  164. Lee JY, Min JH, Han SH, Han J. Transient neonatal myasthenia gravis due to a mother with ocular onset of anti-muscle specific kinase myasthenia gravis. Neuromuscul Disord. 2017;27(7):655–7.

    Article  PubMed  Google Scholar 

  165. Townsel C, Keller R, Johnson K, Hussain N, Campbell WA. Seronegative maternal ocular myasthenia gravis and delayed transient neonatal myasthenia gravis. AJP Rep. 2016;6(1):e133–6.

    Article  PubMed  PubMed Central  Google Scholar 

  166. Gardnerova M, Eymard B, Morel E, Faltin M, Zajac J, Sadovsky O, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology. 1997;48:50–4.

    Article  CAS  PubMed  Google Scholar 

  167. Hoff JM, Daltveit AK, Gilhus NE. Artrogryposis multiplex congenita—a rare fetal condition caused by maternal myasthenia gravis. Acta Neurol Scand Suppl. 2006;183:26–7.

    Article  CAS  PubMed  Google Scholar 

  168. Hacohen Y, Jacobson LW, Byrne S, Norwood F, Lall A, Robb S, et al. Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e57.

    Article  PubMed  Google Scholar 

  169. Midelfart Hoff J, Midelfart A. Maternal myasthenia gravis: a cause for arthrogryposis multiplex congenita. J Child Orthop. 2015;9(6):433–5.

    Article  PubMed  PubMed Central  Google Scholar 

  170. Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, Vernet-der Garabedian B, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest. 1996;98(10):2358–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Polizzi A, Huson SM, Vincent A. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology. 2000;62(5):332–41.

    Article  CAS  PubMed  Google Scholar 

  172. Brueton LA, Huson SM, Cox PM, Shirley I, Thompson EM, Barnes PR, et al. Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. Am J Med Genet. 2000;92(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  173. Mao ZF, Mo XA, Qin C, Lai YR, Hackett ML. Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol. 2012;8(3):161–9.

    Article  PubMed  PubMed Central  Google Scholar 

  174. Zielinski M. Management of myasthenic patients with thymoma. Thorac Surg Clin. 2011;21(1):47–57, vi.

    Article  PubMed  Google Scholar 

  175. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: disease severity and prognosis. Acta Neurol Scand Suppl. 2006;183:24–5.

    Article  CAS  PubMed  Google Scholar 

  176. Bril V, Kojic J, Dhanani A. The long-term clinical outcome of myasthenia gravis in patients with thymoma. Neurology. 1998;51(4):1198–200.

    Article  CAS  PubMed  Google Scholar 

  177. Evoli A, Minisci C, Di Schino C, Marsili F, Punzi C, Batocchi AP, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology. 2002;59(12):1844–50.

    Article  CAS  PubMed  Google Scholar 

  178. Parr JR, Jayawant S. Childhood myasthenia: clinical subtypes and practical management. Dev Med Child Neurol. 2007;49(8):629–35.

    Article  CAS  PubMed  Google Scholar 

  179. Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24(1):101–10.

    Article  CAS  PubMed  Google Scholar 

  180. Della Marina A, Trippe H, Lutz S, Schara U. Juvenile myasthenia gravis: recommendations for diagnostic approaches and treatment. Neuropediatrics. 2014;45(2):75–83.

    Article  PubMed  Google Scholar 

  181. Matthews HJ, Thambundit A, Allen BR. Anti-MuSK-positive myasthenic crisis in a 7-year-old female. Case Rep Emerg Med. 2017;2017:8762302.

    PubMed  PubMed Central  Google Scholar 

  182. Al-Shekhlee A, Kaminski HJ, Ruff RL. Endocrine myopathies and muscle disorders related to electrolyte disturbance. In: Katirji B, Kaminski HJ, Preston D, Shapiro B, Ruff RL, editors. Neuromuscular disorders in clinical practice. Boston: Butterworth Heinemann; 2002. p. 1187–204.

    Google Scholar 

  183. Prudlo J, Koenig J, Ermert S, Juhasz J. Sleep disordered breathing in medically stable patients with myasthenia gravis. Eur J Neurol. 2007;14(3):321–6.

    Article  CAS  PubMed  Google Scholar 

  184. Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S. Sleep apnea in patients with myasthenia gravis. Neurology. 2006;67(1):140–2.

    Article  CAS  PubMed  Google Scholar 

  185. Fernandes Oliveira E, Nacif SR, Alves Pereira N, Fonseca NT, Urbano JJ, Perez EA, et al. Sleep disorders in patients with myasthenia gravis: a systematic review. J Phys Ther Sci. 2015;27(6):2013–8.

    Article  PubMed  PubMed Central  Google Scholar 

  186. Ambrogi V, Mineo TC. Benefits of comprehensive rehabilitation therapy in thymectomy for myasthenia gravis: a propensity score matching analysis. Am J Phys Med Rehabil. 2017;96(2):77–83.

    Article  PubMed  Google Scholar 

  187. Rahbek MA, Mikkelsen EE, Overgaard K, Vinge L, Andersen H, Dalgas U. Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training. Muscle Nerve. 2017;56(4):700–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, The George Washington University, Washington, DC, USA

    Henry J. Kaminski MD

Authors
  1. Henry J. Kaminski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry J. Kaminski MD .

Editor information

Editors and Affiliations

  1. Department of Neurology, George Washington University, Washington, DC, USA

    Henry J. Kaminski

  2. Department of Pharmacology and Physiology, George Washington University, Washington, DC, USA

    Linda L. Kusner

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaminski, H.J. (2018). Treatment of Myasthenia Gravis. In: Kaminski, H., Kusner, L. (eds) Myasthenia Gravis and Related Disorders. Current Clinical Neurology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-73585-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73585-6_11

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-73584-9

  • Online ISBN: 978-3-319-73585-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation